Increases in Cerebrospinal Fluid Caffeine Concentration are Associated with Favorable Outcome after Severe Traumatic Brain injury in Humans
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Caffeine, the most widely consumed psychoactive drug and a weak adenosine receptor antagonist, can be neuroprotective or neurotoxic depending on the experimental model or neurologic disorder. However, its contribution to pathophysiology and outcome in traumatic brain injury (TBI) in humans is undefined. We assessed serial cerebrospinal fluid (CSF) concentrations of caffeine and its metabolites (theobromine, paraxanthine, and theophylline) by high-pressure liquid chromatography/ultraviolet in 97 ventricular CSF samples from an established bank, from 30 adults with severe TBI. We prospectively selected a threshold caffeine level of ≥1 μmol/L (194 ng/mL) as clinically significant. Demographics, Glasgow Coma Scale (GCS) score, admission blood alcohol level, and 6-month dichotomized Glasgow Outcome Scale (GOS) score were assessed. Mean time from injury to initial CSF sampling was 10.77 ± 3.13 h. On initial sampling, caffeine was detected in 24 of 30 patients, and the threshold was achieved in 9 patients. Favorable GOS was seen more often in patients with CSF caffeine concentration ≥ versus < the threshold (55.6 versus 11.8%, P = 0.028). Gender, age, admission CGS score, admission blood alcohol level, and admission systolic arterial blood pressure did not differ between patients with CSF caffeine concentration ≥ versus < the threshold. Increases in CSF concentrations of the caffeine metabolites theobromine and paraxanthine were also associated with favorable outcome ( P = 0.018 and 0.056, respectively). Caffeine and its metabolites are commonly detected in CSF in patients with severe TBI and in an exploratory assessment are associated with favorable outcome. We speculate that caffeine may be neuroprotective by long-term upregulation of adenosine A1 receptors or acute inhibition of A2a receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 1×
“…between caffeine consumption and favorable outcome have been reported for both Parkinson’s and Alzheimer’s disease (Ross et al, 2000; Ascherio et al, 2001; Tan et al, 2003; Lindsay et al, 2002), in those reports, the investigators relied on dietary history to assess caffeine consumption.”
BackgroundAssociation of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“…relationships between caffeine consumption and favorable outcome have been reported for both Parkinson’s and Alzheimer’s disease (Ross et al, 2000; Ascherio et al, 2001; Tan et al, 2003; Lindsay et al, 2002), in those reports, the investigators relied on dietary history to assess caffeine…”
BackgroundAdenosine A2A, but not A1, receptors mediate the arousal effect of caffeine
Huang, Z.-L., Qu, W.-M., Eguchi, N., Chen, J.-F., Schwarzschild, M. A., Fredholm, B. B., Urade, Y., & Hayaishi, O. (2005) · Nature Neuroscience · doi:10.1038/nn1491 · Cited by 640 · cited 9×
“Also supporting a neuroprotectant role for adenosine, administration of an A2AR agonist conferred beneficial effects on outcome or cerebral blood flow after experimental spinal cord injury or TBI (Cassada et al, 2002; Reece et al, 2004; Kochanek et al, 2005), and A1AR upregulation and activation can attenuate neuroinf…”
BackgroundInfluentialCaffeine Withdrawal: A Parametric Analysis of Caffeine Dosing Conditions
Evans, S. M., & Griffiths, R. R. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38135-2 · Cited by 145
Johansson, B., Ahlberg, S., van der Ploeg, I., Brené, S., Lindefors, N., Persson, H., & Fredholm, B. B. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00165391 · Cited by 144 · cited 2×
“However, effects of caffeine can also be mediated at the adenosine A1 receptor (A1AR), and results depend on whether acute or long-term exposure is involved (Johansson et al, 1993; Georgiev et al, 1993; Al Moutaery et al, 2003).”
BackgroundClark, R. S. B., Carcillo, J. A., Kochanek, P. M., Obrist, W. D., Jackson, E. K., Mi, Z., Wisneiwski, S. R., Bell, M. J., & Marion, D. W. (1997) · Neurosurgery · doi:10.1097/00006123-199712000-00010 · Cited by 91 · cited 3×
“This could magnify the benefit anticipated from the massive adenosine surge that routinely follows TBI (Clark et al, 1997), and is also seen in response to secondary insults in humans (Bell et al, 2001).”
BackgroundSelf-citation
Cited by
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
“of favorable prognosis in diseases involving neurodegeneration [138,139].”
BackgroundAdenosine signaling and function in glial cells
Boison, D., Chen, J.-F., & Fredholm, B. B. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.131 · Cited by 306
Pharmacokinetics and metabolism of natural methylxanthines in animal and man
Arnaud, M. J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_3 · Cited by 259
Chronic Caffeine Exposure Attenuates Blast-Induced Memory Deficit in Mice
Ning, Y.-L., Yang, N., Chen, X., Zhao, Z.-A., Zhang, X.-Z., Chen, X.-Y., Li, P., Zhao, Y., & Zhou, Y.-G. (2015) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2015.10.003 · Cited by 24
Metadata
- Authors
- Sachse, K. T., Jackson, E. K., Wisniewski, S. R., Gillespie, D. G., Puccio, A. M., Clark, R. S., Dixon, C. E., & Kochanek, P. M.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2007-08-08
- Volume
- 28
- Issue
- 2
- Pages
- 395-401
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W1995698083
- Cited by
- 49
- References
- 7
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.